Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarctionResearch in context

• Published in: EBioMedicine Vol. 46; pp. 264 - 273
• Main Authors: Linn E. Fosshaug, Romain A. Colas, Anne K. Anstensrud, Ida Gregersen, Ståle Nymo, Ellen L. Sagen, Annika Michelsen, Leif E. Vinge, Erik Øie, Lars Gullestad, Bente Halvorsen, Trond V. Hansen, Pål Aukrust, Jesmond Dalli, Arne Yndestad
• Format: Journal Article
• Language: English
• Published: Elsevier 01-08-2019
• ISSN: 2352-3964; 2352-3964

Background: Termination of acute inflammation is an active process orchestrated by lipid mediators (LM) derived from polyunsaturated fatty acids, referred to as specialized pro-resolving mediators (SPM). These mediators also provide novel therapeutic opportunities for treating inflammatory disease. However, the regulation of these molecules following acute myocardial infarction (MI) remains of interest. Methods: In this prospective observational study we aimed to profile plasma levels of SPMs in ST-elevation MI (STEMI) patients during the first week following MI. Plasma LM concentrations were measured in patients with STEMI (n = 15) at three time points and compared with stable coronary artery disease (CAD; n = 10) and healthy controls (n = 10). Findings: Our main findings were: (i) Immediately after onset of MI and before peak troponin T levels, STEMI patients had markedly increased levels of SPMs as compared with healthy controls and stable CAD patients, with levels of these mediators declining during follow-up. (ii) The increase in SPMs primarily reflected an increase in docosapentaenoic acid- and docosahexaenoic acid-derived protectins. (iii) Several individual protectins were correlated with the rapid increase in neutrophil counts, but not with CRP. (iv) A shift in 5-LOX activity from the leukotriene B4 pathway to the pro-resolving RvTs was observed. Interpretation: The temporal regulation of SPMs indicates that resolution mechanisms are activated early during STEMI as part of an endogenous mechanism to initiate repair. Thus strategies to boost the activity and/or efficacy of these endogenous mechanisms may represent novel therapeutic opportunities for treatment of patients with MI. Fund: This work was supported by grants from the South-Eastern Norwegian regional health authority, the European Research Council under the European Union's Horizon 2020 research and innovation program, a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society, and the Barts Charity. Keywords: Myocardial infarction, Resolution, Inflammation, Specialized pro-resolving mediators, Polyunsaturated fatty acids